glioma

News

Servier snaps up cancer biotech Day One in $2.5bn deal

Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.

News

CHMP backs Ipsen drug for childhood brain cancer

Ipsen's Ojemda is on course to become the first targeted medicine in the EU for some children with a form of brain cancer known as low-grade glioma.

News

Sand picture of balloons as brains, flown by man and child

Jazz gets FDA okay for Chimerix brain cancer drug

Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 K27M mutations.

News

Jazz swings further into cancer with Chimerix takeover

Jazz has reached an agreement to buy Chimerix for around $935 million, adding a brain cancer drug heading for an FDA approval decision in August.

News

Servier bags FDA okay for glioma drug from $2bn Agios buy

The FDA has approved Servier's vorasidenib for two forms of glioma, becoming the first targeted therapy for this aggressive and incurable form of brain cancer.

News

Ipsen builds again, licensing Day One glioma drug

Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceutical

Servier snaps up cancer biotech Day One in $2.5bn deal

CHMP backs Ipsen drug for childhood brain cancer

Jazz gets FDA okay for Chimerix brain cancer drug

Jazz swings further into cancer with Chimerix takeover

Servier bags FDA okay for glioma drug from $2bn Agios buy

Ipsen builds again, licensing Day One glioma drug

Hernexeos and what’s next, with Vicky Brown

Using AI-driven synthetic personas to take your insights fur...

glioma

Editor's Picks